Regeneron and Sanofi to present new analyses from Praluent injection trials

Presentations include results from ODYSSEY APPRISE, an open-label study in 16 European countries and Canada in patients with severe hypercholesterolemia at high cardiovascular risk.

This year's presentations include results from ODYSSEY APPRISE, an open-label study in 16 European countries and Canada in patients with severe hypercholesterolemia at high cardiovascular risk, as well as new post hoc analyses from the ODYSSEY clinical trial program. Additionally, an analysis of the risk of atherosclerotic cardiovascular disease events in a real-world population of patients with diabetes treated with statins will also be presented.

Praluent is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), which is approved in more than 50 countries worldwide, including the US, Japan, Canada, Switzerland, Mexico, Brazil and the European Union (EU). The effect of Praluent on cardiovascular (CV) morbidity and mortality has not been determined.

Presentations at the ESC Congress 2017 include

1) Oral Presentation:

2) Poster Presentations: